It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. Tumour ecosystems feature diverse immune cell types. Myeloid cells, in particular, are prevalent and have a well-established role in promoting the disease. In our study, we profile approximately 900,000 cells from 25 treatment-naive patients with adenocarcinoma and squamous-cell carcinoma by single-cell and spatial transcriptomics. We note an inverse relationship between anti-inflammatory macrophages and NK cells/T cells, and with reduced NK cell cytotoxicity within the tumour. While we observe a similar cell type composition in both adenocarcinoma and squamous-cell carcinoma, we detect significant differences in the co-expression of various immune checkpoint inhibitors. Moreover, we reveal evidence of a transcriptional “reprogramming” of macrophages in tumours, shifting them towards cholesterol export and adopting a foetal-like transcriptional signature which promotes iron efflux. Our multi-omic resource offers a high-resolution molecular map of tumour-associated macrophages, enhancing our understanding of their role within the tumour microenvironment.
Myeloid cell populations play a critical role in lung cancer progression. Here, the authors use scRNA-seq and spatial transcriptomics to identify changes in the phenotype of macrophages within the tumour microenvironment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); University of Cambridge, Department of Haematology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); Wellcome Trust—Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK (GRID:grid.14105.31) (ISNI:0000000122478951)
2 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); Wellcome Genome Campus, European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672)
3 Wellcome Genome Campus, European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); DKFZ, Division of Artificial Intelligence in Oncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
4 Wellcome Genome Campus, European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672)
5 Sanofi, Precision Medicine and Computational Biology, Cambridge, USA (GRID:grid.417555.7) (ISNI:0000 0000 8814 392X)
6 Sanofi, Precision Medicine and Computational Biology, Paris, France (GRID:grid.417924.d)
7 Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); University of West Attica, Medical Image and Signal Processing Laboratory (MEDISP), Department of Biomedical Engineering, Athens, Greece (GRID:grid.499377.7) (ISNI:0000 0004 7222 9074)
8 Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); Wellcome Genome Campus, European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); DKFZ, Division of Artificial Intelligence in Oncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
9 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672)
10 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); University of Cambridge, Department of Haematology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); University of Copenhagen, Biotech Research & Innovation Centre (BRIC), Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)